LA JOLLA, Calif.--(BUSINESS WIRE)--In its continued interrogation of stem cell biology to guide cell fate for therapeutic benefit, Fate Therapeutics, Inc. has expanded its management team through the addition of Dan Shoemaker, Ph.D., as its chief technology officer. Under Shoemaker’s leadership, Fate Therapeutics is developing and implementing innovative molecular detection technologies to identify, characterize and quantify cell state. Fate Therapeutics is developing small molecules to activate the body’s own cells for regenerative medicine and to create and differentiate virus-free induced pluripotent stem (iPS) cells for drug discovery and therapeutic development.
